Rigel highlights GAVRETO data at ESMO Congress 2026
Rigel says it will present new pralsetinib data in oral and poster presentations on RET fusion-positive cancers at the ESMO Congress 2026.
Rigel says it will present new pralsetinib data in oral and poster presentations on RET fusion-positive cancers at the ESMO Congress 2026.